Adverse Events with Obesity Drugs (GLP-1s): Management Guide
GI side effects hit 30-50% of GLP-1 users and cause most early stops. See dose escalation, stopping rules, and pancreatitis risk factors to keep patients on therapy.
8 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 8 of 8 clinical reviews.
GI side effects hit 30-50% of GLP-1 users and cause most early stops. See dose escalation, stopping rules, and pancreatitis risk factors to keep patients on therapy.
A prescriber- and pharmacist-level guide to GLP-1 receptor agonist drug classes, dosing, prior authorization strategy, step-therapy requirements, and appeals, with primary-source citations throughout.
Clinician-focused drug-drug interaction reference for GLP-1 receptor agonists including semaglutide, liraglutide, dulaglutide, tirzepatide, and exenatide. Covers gastroparesis-mediated absorption changes, hypoglycemia stacking, warfarin monitoring, and oral contraceptive efficacy.
A clinician-level guide to the GLP-1 receptor agonist drug class, including baseline workup, ongoing monitoring, dose titration, adverse-effect management, and cardiovascular outcome data.
A clinical-level review of GLP-1 receptor agonist use across special populations, pregnancy, renal impairment, heart failure, pediatrics, and more, with dosing guidance, trial data, and guideline citations.
A prescriber-level monograph covering GLP-1 receptor agonist pharmacology, approved indications, landmark trial data, dosing, adverse effects, and clinical selection guidance.
A clinical guide to selecting among GLP-1 receptor agonists, semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, based on weight, CV risk, renal function, dosing frequency, and cost. Written for prescribers and clinical pharmacists.
A clinical-level guide to GLP-1 receptor agonist titration schedules, tapering protocols, dose adjustments for tolerability, and restart strategies, written for prescribers and dispensing pharmacists.